# Yanyang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/yanyang

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.scyysw.cn/
- Total disclosed funding: $15M
- Latest round: Series A (Jan 26, 2026)
- Investors on record: 5

## About

Founded in 2019 and based in Chengdu, China, Sichuan Yanyang Biotechnology Co., Ltd., trading as Yanyang, is a drug developer that focuses on the development of therapeutic biological products (live microecological bacteria) and microecological products in the field of health. In 2019, the company established the toxicology evaluation of vaginal bacteria. In 2020, it established a bacterial medicine intelligent manufacturing platform and an anaerobic live bacteria pilot test platform. It was honoured the Science and Technology-based Small and Medium-sized Enterprises, and National High-tech Enterprises. Yanyang has technologies such as high-throughput screening of anaerobic microorganisms, evaluation of high-efficiency bacteria drugs, and storage and transportation of live bacteria. It also created a resource bank of human anaerobic microorganisms. In January 2026, Yanyang raised a series A+ funding from returning investor Tao Capital.

Yanyang's pipeline of products can be categorized into three types which are human bacterial reservoirs, reproductive tract bacteriophages, and intestinal bacteria. Products within include vaginal bacteria and intestinal bacteria. Intestinal bacteria drugs are used in chemotherapy-related diarrhea, tumors, metabolic diseases, autoimmunity and other fields. The products can be used in the treatment of diseases in relevant parts of the human body.

The company will use the latest funding to accelerate preclinical research on core strains and the construction of a GMP-grade live bacteria formulation pilot-scale platform.

## Funding rounds

- Series A, Jan 26, 2026 — Tao Capital
- Series A, Aug 1, 2022, $15M — CDF-Capital, Dalton Venture, Chengdu Science and Technology Innovation Investment Group, Zhongxi Capital

## Investors

- CDF-Capital (https://capitalatlas.ai/funds/cdf-capital) — Series A
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series A
- Chengdu Science and Technology Innovation Investment Group — Series A
- Zhongxi Capital (https://capitalatlas.ai/funds/zhongxi-capital) — Series A
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series A